Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from <scp>VERTIS CV</scp>
Ertugliflozin was generally associated with lowering UA overall and across subgroups compared with placebo, and numerically reduced rates of gout-related outcome events.
Authors
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Samuel E. Dagogo-Jack (ORCID: https://orcid.org/0000-0001-5318-9677)
- Margaret Noyes Essex (ORCID: https://orcid.org/0000-0001-8168-9791)
- Vikas S. Sridhar (ORCID: https://orcid.org/0000-0001-7947-1822)
- Nilo B. Cater (ORCID: https://orcid.org/0000-0001-5868-8643)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-5698-7946)
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Yujie Zhao (ORCID: https://orcid.org/0000-0003-2896-4955)
- Richard E. Pratley
- James P. Mancuso (ORCID: https://orcid.org/0000-0002-5722-1360)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Parkland Health & Hospital System (US)
- University Health Network (CA)
- Karolinska University Hospital (SE)
- University of Tennessee Health Science Center (US)
- Pfizer (United States) (US)
- Toronto General Hospital (CA)
- Karolinska Institutet (SE)
- Translational Research Institute for Metabolism and Diabetes (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/dom.15895
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- American Diabetes Association
- American Society of Nephrology
- Pfizer
- European Foundation for the Study of Diabetes